Trial Profile

A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tesetaxel (Primary)
Indications Bladder cancer
Focus Therapeutic Use
Sponsors Genta (CEASED)

Most Recent Events

04 Nov 2011 Planned number of patients changed from 27 to 33 as reported by ClinicalTrials.gov.
28 Oct 2010 New source identified and integrated (Memorial Sloan-Kettering Cancer Center).
05 Oct 2010 Planned end date (December 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com